Review: taking Coumadin and Norvasc together


Summary

Drug interactions are reported among people who take Coumadin and Norvasc together. This review analyzes the effectiveness and drug interactions between Coumadin and Norvasc. It is created by eHealthMe based on reports of 10,334 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Coumadin

Coumadin has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Coumadin 101,806 users)

Norvasc

Norvasc has active ingredients of amlodipine besylate. It is often used in high blood pressure. (latest outcomes from Norvasc 99,486 users)

On Sep, 18, 2016

10,334 people who take Coumadin, Norvasc are studied.


Number of reports submitted per year:

Coumadin and Norvasc drug interactions.

Drug effectiveness over time:

Coumadin:
  • < 1 month: 25.0% - (2 of 8 people)
  • 1 - 6 months: 50.0% - (8 of 16 people)
  • 6 - 12 months: 71.0% - (5 of 7 people)
  • 1 - 2 years: 61.0% - (8 of 13 people)
  • 2 - 5 years: 77.0% - (14 of 18 people)
  • 5 - 10 years: 58.0% - (7 of 12 people)
  • 10+ years: 94.0% - (18 of 19 people)
  • not specified: 100.0% - (1 of 1 people)
Norvasc:
  • < 1 month: 0.0% - (0 of 3 people)
  • 1 - 6 months: 21.0% - (3 of 14 people)
  • 6 - 12 months: 37.0% - (3 of 8 people)
  • 1 - 2 years: 22.0% - (4 of 18 people)
  • 2 - 5 years: 59.0% - (13 of 22 people)
  • 5 - 10 years: 58.0% - (10 of 17 people)
  • 10+ years: 73.0% - (11 of 15 people)
  • not specified: 0.0% - (0 of 1 people)

Drug effectiveness by gender:

Coumadin:
  • female: 50.0% - (18 of 36 people)
  • male: 77.0% - (45 of 58 people)
Norvasc:
  • female: 40.0% - (15 of 37 people)
  • male: 47.0% - (29 of 61 people)

Drug effectiveness by age:

Coumadin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 60.0% - (3 of 5 people)
  • 50-59: 86.0% - (13 of 15 people)
  • 60+: 63.0% - (46 of 73 people)
Norvasc:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 20.0% - (1 of 5 people)
  • 50-59: 35.0% - (5 of 14 people)
  • 60+: 48.0% - (38 of 78 people)

Most common drug interactions over time *:

< 1 month:
  • international normalised ratio increased
  • diarrhoea
  • dyspnoea
  • multi-organ failure
  • renal failure
  • gastrointestinal haemorrhage
  • neutropenia
  • septic shock
  • rash macular
  • renal failure acute
1 - 6 months:
  • dyspnoea
  • gastrointestinal haemorrhage
  • oedema peripheral
  • cellulitis
  • chest pain
  • headache
  • anxiety
  • cardiac failure congestive
  • cerebrovascular accident
  • haemorrhoids
6 - 12 months:
  • dyspnoea
  • dizziness
  • international normalised ratio increased
  • fall
  • hypotension
  • atrial fibrillation
  • renal failure acute
  • bradycardia
  • dyspepsia
  • epistaxis
1 - 2 years:
  • hypertension
  • ischaemic stroke
  • atherosclerosis
  • type 2 diabetes mellitus
  • nephrogenic systemic fibrosis
  • nausea
  • asthenia
  • diarrhoea
  • pyrexia
  • anxiety
2 - 5 years:
  • anxiety
  • anaemia
  • cerebrovascular accident
  • depression
  • infection
  • loose tooth
  • osteonecrosis
  • blood disorder
  • cardiac disorder
  • impaired healing
5 - 10 years:
  • anaemia
  • anxiety
  • mobility decreased
  • nephrogenic systemic fibrosis
  • pain
  • general physical health deterioration
  • international normalised ratio increased
  • rash
  • discomfort
  • emotional distress
10+ years:
  • international normalised ratio increased
  • gingival bleeding
  • haemoglobin decreased
  • melaena
  • occult blood positive
  • dizziness
  • upper gastrointestinal haemorrhage
  • anaemia
  • coagulopathy
  • pain - knee
not specified:
  • dyspnoea
  • pain
  • nausea
  • fatigue
  • asthenia
  • oedema peripheral
  • atrial fibrillation
  • international normalised ratio increased
  • anxiety
  • anaemia

Most common drug interactions by gender *:

female:
  • nausea
  • pain
  • dyspnoea
  • asthenia
  • fatigue
  • atrial fibrillation
  • oedema peripheral
  • anaemia
  • international normalised ratio increased
  • anxiety
male:
  • dyspnoea
  • pain
  • international normalised ratio increased
  • cardiac failure congestive
  • oedema peripheral
  • fatigue
  • anxiety
  • atrial fibrillation
  • asthenia
  • nausea

Most common drug interactions by age *:

0-1:
  • pleural effusion
  • disseminated intravascular coagulation
  • hepatic function abnormal
  • rhabdomyolysis
  • anaemia
  • pneumonia
  • pulmonary hypertension
  • pyrexia
  • agitation
  • bradycardia
2-9:
  • fall
  • hip fracture
  • confusional state
  • constipation
  • contusion
  • drug administration error
  • feeling abnormal
  • hallucination, visual
  • hypoacusis
  • road traffic accident
10-19:
  • contusion
  • subdural haematoma
  • syncope
  • cardiac arrest
  • deep vein thrombosis
  • dyspnoea
  • gait disturbance
  • hypotension
  • skull fracture
  • abdominal distension
20-29:
  • pain
  • nephrogenic systemic fibrosis
  • mobility decreased
  • arthralgia
  • oedema
  • pain in extremity
  • skin tightness
  • oedema peripheral
  • skin disorder
  • skin hyperpigmentation
30-39:
  • pain
  • nephrogenic systemic fibrosis
  • anxiety
  • chest pain
  • skin induration
  • skin tightness
  • dyspnoea
  • pyrexia
  • vomiting
  • nausea
40-49:
  • dyspnoea
  • headache
  • international normalised ratio increased
  • chest pain
  • oedema peripheral
  • pain
  • nausea
  • gastrooesophageal reflux disease
  • pulmonary embolism
  • pyrexia
50-59:
  • pain
  • anxiety
  • nausea
  • oedema peripheral
  • depression
  • fatigue
  • dyspnoea
  • anaemia
  • arthralgia
  • pain in extremity
60+:
  • dyspnoea
  • international normalised ratio increased
  • atrial fibrillation
  • asthenia
  • nausea
  • pain
  • anaemia
  • fatigue
  • cardiac failure congestive
  • oedema peripheral

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Coumadin and Norvasc?

Can you answer these questions?

More questions for: Coumadin, Norvasc

You may be interested in these reviews

More reviews for: Coumadin, Norvasc

On eHealthMe, Coumadin (warfarin sodium) is often used to treat atrial fibrillation/flutter. Norvasc (amlodipine besylate) is often used to treat high blood pressure. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.